Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma
Myoung Joo Kang(Inje University Haeundae Paik Hospital), Myung‐Hwan Kim(Korea Aerospace Research Institute), Sung Koo Lee(Ulsan College), Dong Wan Seo(Dankook University), Jae‐Lyun Lee(Ulsan College), Sang Soo Lee(Chungbuk National University Hospital), Shin Ahn(Ulsan College), Tae Won Kim(Ulsan College), Sung Sook Lee(Inje University Haeundae Paik Hospital), Do Hyun Park(Massachusetts Institute of Technology)
Cited by 37
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
|JAMA Oncology|2017|846
TIMP-2 Mediated Inhibition of Angiogenesis
|Cell|2003|510